Login to Your Account



Tularik, Amgen Entering $125M Oncology Targets Collaboration

By Randall Osborne


Thursday, May 22, 2003
Aiming to forge deeper into the cancer market, Amgen Inc. is taking from its well-stocked coffers to buy 21.3 percent of Tularik Inc. - $35 million worth of newly issued stock at $10 per share - as part of a deal that includes an oncology collaboration and a total of $125 million in committed funding. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription